September 30, 2024 by Robin Foster Blood cancer is not a diagnosis anyone wants to receive, but understanding the different types of this disease and how best to catch them early is essential, one expert says. First, blood cancers are far more common than you might think: One person in the United States is diagnosed...
Tag: <span>Blood cancers</span>
Post
Potent results from a new immune treatment seen in patients with hard-to-treat blood cancers
by Peter MacCallum Cancer Centre Credit: Pixabay/CC0 Public Domain All patients in the Phase I / II clinical trial of glofitamab had Diffuse Large B-Cell Lymphoma (DLBCL) and their cancer had relapsed or was no longer responding to conventional treatments, including CAR T-cell therapy. Peter Mac treated the first patients in the world with glofitamab and was...
Post
Adults with blood cancers respond to booster, not initial dose of COVID-19 vaccine
WILEY People with hematologic malignancies—or blood cancers including leukemia, lymphoma, and multiple myeloma—have an impaired immune system due to their disease and its treatment, putting them at risk of severe COVID-19 infection and experiencing a reduced response to COVID-19 vaccination. In a recent study published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society,...
Post
Immunity boosting treatment enhances CAR-T cell therapy for blood cancers
by Julia Evangelou Strait, Washington University School of Medicine A study by researchers at Washington University School of Medicine in St. Louis shows that treatment with an immunity boosting protein called interleukin 7 (IL-7) after an infusion of genetically modified T cells causes the cancer-fighting CAR-T cells to grow in number and become more effective at...
Post
How a genetic mutation affects the body’s immune system response to viruses, development of blood cancers – immunology – genetics – research Inbox
by University of Saskatchewan Graphical abstract. Credit: Cell Reports (2022). DOI: 10.1016/j.celrep.2022.110856 The body’s innate immune system, active from birth, is the first line of defense against viruses and other pathogens that cause disease. Using vaccination as an example, after receiving a vaccine, pain, redness, or swelling may occur at the injection site. This response is a...
Post
Study finds mutated protein structure at the root of blood cancers
Stanford University researchers working on a project supported by a U.S. National Science Foundation grant have determined the structure of a large signalling protein in response to infection, inflammation and immune cell generation. The system reveals how the protein Janus kinase, or JAK, transmits signals sent by immune cell growth factors called cytokines. When the structure of the...
Post
Study predicts who may benefit from CAR-T cell therapy for blood cancers
by Krista Conger, Stanford University Medical Center Fig. 1: IHC demonstrates CD19−/lo disease postaxi-cel and quantitative flow cytometry of LBCL preaxi-cel therapy is associated with disease progression. a Preaxi-cel H-scores did not distinguish long-term responders and those with progression postaxi-cel (P = 0.32 by t-test, P = 1 Fisher’s exact test). Waterfall plot of CD19 IHC H-scores preaxi-cel therapy (n = 44...
Post
Convalescent plasma improves survival in COVID-19 patients with blood cancers
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO SAN ANTONIO (June 17, 2021) — Convalescent plasma therapy was associated with better survival in blood cancer patients hospitalized with COVID-19, especially in sicker patients. The findings by the COVID-19 and Cancer Consortium (CCC19) are newly published in the peer-reviewed journal JAMA Oncology. The Mays Cancer Center, home...
Post
Another promising approach for hard-to-treat blood cancers
by Peter MacCallum Cancer Centre Credit: CC0 Public Domain For patients with some hard-to-treat blood cancers, a simple “off-the-shelf” immunotherapy is achieving promising results. A clinical trial of the developmental drug Glofitamab has shown it can produce a durable “complete response”—meaning the cancer became undetectable—in patients with relapsed or treatment resistant B-cell lymphomas. One option for these...
Post
Utah researchers illuminate potential precursors of blood cancers
HUNTSMAN CANCER INSTITUTE IMAGE: CLINT MASON, JULIE FEUSIER, AND SASI ARUNACHALAM CREDIT: HUNTSMAN CANCER INSTITUTE (FOR MASON AND FEUSIER) AND ST. JUDE (FOR ARUNACHALAM) SALT LAKE CITY – Utah researchers report significant new insights into the development of blood cancers. In work published today in Blood Cancer Discovery, a journal of the American Association for Cancer Research, scientists describe...
- 1
- 2